Platelet Function After Cardiac Surgery. (PLFICS)

Insel Gruppe AG, University Hospital Bern

Status

Enrolling

Conditions

Platelet Dysfunction

Treatments

Device: Autologous cell salvage with i-Sep SAME device

Device: Autologous blood cell salvage with in-house device

Study type

Interventional

Funder types

Other

Identifiers

NCT06405516

BASEC 2023-D0074

Details and patient eligibility

About

Intraoperative cell salvage is commonly used in cardiac surgery to reduce the administration of allogeneic red blood cells and thus improve the outcome for the patient. When processing the salvaged blood, however, a large part of the patient's plasma is washed out. This is a disadvantage with regard to an optimal coagulation situation after cardiac surgery.

There are currently various cell saver systems on the market. According to the manufacturers, the plasma is returned to the patient in different quantities as part of the processing procedure. Thus, it can be assumed that in addition to red blood cells, platelets (part of plasma) are retransfused and contribute to an optimized coagulation. Unfortunately, there is a lack of studies in this regard in the cardiac surgery population.

The investigators aim to study the performance of two different cell saver devices regarding preservation of platelet number and function.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age >18 years
Elective high risk cardiac surgery with cardiopulmonary bypass usage
Cardiopulmonary bypass time > 120 minutes
Written informed consent

Exclusion criteria

Preoperative use of oral or intravenous anti-coagulants or antiplatelet agents (except aspirin)
Inability to understand and sign the informed consent form (e.g. language problems, dementia, mental disorders).